MedPath

Efficacy of systemic venous sampling of FGF23 to localize responsible tumors in tumor-induced rickets/osteomalacia

Not Applicable
Recruiting
Conditions
Tumor-induced rickets/osteomalacia
Registration Number
JPRN-UMIN000031742
Lead Sponsor
The University of Tokyo Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with serious kidney disease(eGFR<30 mL/min/1.73m2). Patients who are pregnant. Patients who are considered ineligible for the study by investigators' decision.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Whether a combination of systemic venous sampling of FGF23 and imaging studies, such as FDG-PET/CT and octreoscan, shows higher sensitivity and positive predictive value compared to imaging studies alone to localize responsible tumors in TIO.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath